Zoryl 3 Tablet contains Glimepiride 3mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Zoryl 3 is typically prescribed as an adjunct to diet and exercise when these measures alone are insufficient to achieve adequate blood glucose levels. The medication is effective in lowering both fasting and postprandial blood glucose concentrations, contributing to overall glycemic stability. It is important to initiate therapy at the lowest effective dose and adjust according to patient response and glycemic targets, while monitoring for potential hypoglycemia, a common adverse effect associated with sulfonylureas. Caution is advised in patients with hepatic or renal impairment, and it should be used with care in elderly patients due to increased risk of hypoglycemia. Zoryl 3 is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, and known hypersensitivity to sulfonylureas. Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy and guide dose adjustments. Patient education on recognizing symptoms of hypoglycemia and adherence to prescribed lifestyle modifications is essential for optimal treatment outcomes.